BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday.

Other research analysts also recently issued reports about the company. FBR & Co reissued a “buy” rating and issued a $6.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JPMorgan Chase & Co. reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Jefferies Group boosted their price objective on BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Friday, August 5th. JMP Securities downgraded BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Finally, Piper Jaffray Cos. raised BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $5.00 to $8.00 in a research note on Friday, August 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.93.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 5.02 on Tuesday. The company’s market capitalization is $369.97 million. BioCryst Pharmaceuticals has a 12-month low of $1.63 and a 12-month high of $10.98. The company’s 50 day moving average price is $4.40 and its 200-day moving average price is $3.77.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.08. The firm had revenue of $7.80 million for the quarter, compared to the consensus estimate of $5.94 million. BioCryst Pharmaceuticals had a negative return on equity of 232.12% and a negative net margin of 313.02%. The business’s quarterly revenue was down 29.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.20) EPS. Equities analysts forecast that BioCryst Pharmaceuticals will post ($0.95) earnings per share for the current fiscal year.

In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 5,864 shares of the business’s stock in a transaction that occurred on Friday, August 12th. The stock was sold at an average price of $5.18, for a total transaction of $30,375.52. Following the completion of the sale, the insider now directly owns 128,745 shares of the company’s stock, valued at approximately $666,899.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $5.00, for a total value of $20,232,950.00. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. VHCP Management II LLC raised its stake in shares of BioCryst Pharmaceuticals by 22.0% in the second quarter. VHCP Management II LLC now owns 5,721,142 shares of the biotechnology company’s stock worth $16,248,000 after buying an additional 1,031,707 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 3,526,530 shares of the biotechnology company’s stock worth $10,016,000 after buying an additional 283,202 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of BioCryst Pharmaceuticals by 6.2% in the third quarter. BlackRock Fund Advisors now owns 3,027,595 shares of the biotechnology company’s stock worth $13,352,000 after buying an additional 177,357 shares in the last quarter. RTW Investments LLC raised its stake in shares of BioCryst Pharmaceuticals by 13.3% in the second quarter. RTW Investments LLC now owns 2,237,066 shares of the biotechnology company’s stock worth $6,353,000 after buying an additional 263,134 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in shares of BioCryst Pharmaceuticals by 5.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,956,570 shares of the biotechnology company’s stock worth $8,628,000 after buying an additional 102,535 shares in the last quarter. 70.29% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

5 Day Chart for NASDAQ:BCRX

Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.